When starting your first semaglutide GLP-1 injection for weight loss, its important to know what to expect
Variables and outcomes The variables of interest included patient age, sex, benefit plan type, employment status, region (i.e., Northeast, North Central, South and West), claim-based frailty index, Charlson Comorbidity Index (CCI), rurality, as well as concurrent medical conditions (Table 1)
Furthermore, the interaction between these receptors helps investigators understand how the body manages glucose and lipid levels
Explore the results here: Obesity as a therapeutic area presents unique challenges in long-term efficacy and patient adherence in late-stage trials
Another 2025 review revealed that injection-site reactions are more likely with tirzepatide than with semaglutide (but keep in mind these reactions are almost always mild and temporary)